Trial Profile
The Effects of an ER Beta Agonist (Lilly Compound LY500307) on Estradiol-withdrawal-induced Mood Symptoms in Women With Past Perimenopausal Depression
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Erteberel (Primary) ; Estradiol
- Indications Depression; Mood disorders
- Focus Therapeutic Use
- 28 Dec 2022 Planned number of patients changed from 54 to 80.
- 11 Jun 2021 Planned End Date changed from 31 Dec 2022 to 31 Dec 2025.
- 11 Jun 2021 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2025.